A Study of GWP42006 in People With Focal Seizures - Part B
NCT ID: NCT02365610
Last Updated: 2022-12-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
162 participants
INTERVENTIONAL
2016-03-31
2017-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects who satisfy all inclusion and none of the exclusion criteria will enter a four-week baseline period, followed by a two-week dose escalation period (400 mg twice daily for one week, then 600 mg twice daily for one week), a six-week stable treatment period (800 mg twice daily) and a 12-day taper period. Subjects will be required to attend eight study visits. A follow-up phone call will take place four weeks after last dose.
Subjects will be randomized to receive in a 1:1 ratio, GWP42006 or placebo. Subjects will be required to record a daily diary with information about their seizures, investigational medicinal product (IMP) and concomitant antiepileptic drug (AED) administration.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GWP42006
GWP42006
GWP42006
Placebo control
Placebo
Placebo Control
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GWP42006
Placebo Control
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Well-documented history of focal epilepsy, compatible electroencephalogram and clinical history.
* Documented computerized tomography / magnetic resonance imaging that shows no progressive neurologic abnormality.
* Has focal seizures despite prior treatment with at least two AEDs (whether as monotherapies or in combination).
* Currently treated with one to three AEDs.
* All medications or interventions for epilepsy (including ketogenic diet) must have been stable for one month prior to screening and the subject is willing to maintain a stable regimen throughout the study.
* Subject is willing to keep any factors expected to affect seizures stable (such as the level of alcohol consumption and smoking).
The patient may not enter Part B of the study if ANY of the following apply:
* Time of onset of focal epilepsy treatment is less than two years prior to enrolment.
* Patient has seizures that are not of focal onset.
* Patient only has focal seizures without impairment of consciousness or awareness and without an observable motor component (even if autonomic component is present).
* Episode(s) of status epilepticus during one year prior to screening.
* History of pseudo-seizures.
* Vagus Nerve Stimulation, Deep Brain Stimulation, Responsive Neurostimulator System or other epilepsy neurostimulation device have been implanted or activated less than one year prior to screening, and/or stimulation parameters have been stable for less than one month, and/or battery life of unit not anticipated to extend for duration of trial.
* Had epilepsy surgery within one year of screening.
* Subject has clinically significant unstable medical conditions other than epilepsy.
* Subject has an illness in the four weeks prior to screening or randomization, other than epilepsy, which in the opinion of the investigator would affect seizure frequency.
* Subject has significantly impaired hepatic function at Visit 1.
* Active suicidal plan/intent in the past six months, or a history of suicide attempt in the last two years, or more than one lifetime suicide attempt .
* Subject is currently using or has in the past used recreational or medicinal cannabis, or cannabinoid based medications within the three months prior to screening and is unwilling to abstain for the duration for the study.
* Subject has taken St John's Wort in the last two weeks and/or is unwilling to abstain throughout the study.
* Subject has consumed grapefruit or grapefruit juice three days prior to randomization and/or unwilling to abstain in the three days prior to Visits B2 and B7.
* Any known or suspected hypersensitivity to cannabinoids, sesame oil or any of the excipients of the IMP(s).
* Subjects who have received an IMP within the 12 weeks prior to the screening visit.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jazz Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Havířov, , Czechia
Hradec Králové, , Czechia
Prague, , Czechia
Rychnov nad Kněžnou, , Czechia
Budapest, , Hungary
Esztergom, , Hungary
Hódmezővásárhely, , Hungary
Kecskemét, , Hungary
Pécs, , Hungary
Szombathely, , Hungary
Bologna, , Italy
Pavia, , Italy
Rome, , Italy
Bydgoszcz, , Poland
Elblag, , Poland
Golub-Dobrzyń, , Poland
Katowice, , Poland
Krakow, , Poland
Warsaw, , Poland
Wroclaw, , Poland
Barcelona, , Spain
Madrid, , Spain
Birmingham, , United Kingdom
Glasgow, , United Kingdom
Great Yarmouth, , United Kingdom
Stoke-on-Trent, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Brodie MJ, Czapinski P, Pazdera L, Sander JW, Toledo M, Napoles M, Sahebkar F, Schreiber A; GWEP1330 Study Group. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res. 2021 Dec;6(6):528-536. doi: 10.1089/can.2020.0075. Epub 2021 Feb 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-002594-11
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
GWEP1330 Part B
Identifier Type: -
Identifier Source: org_study_id